Načítá se...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2020
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094159/ https://ncbi.nlm.nih.gov/pubmed/33316104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|